Home/Pipeline/HCB206

HCB206

Autoimmune Diseases

PreclinicalActive

Key Facts

Indication

Autoimmune Diseases

Phase

Preclinical

Status

Active

Company

HanchorBio

About HanchorBio

A clinical-stage biotech using its FBDB™ platform to develop multi-specific fusion proteins targeting immune checkpoints for oncology and autoimmune diseases.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
Humira (Adalimumab) Biosimilar	NeuClone	Early Preclinical	Active
HBM7020	Harbour BioMed	Discovery	Out-Licensed
R2006	Harbour BioMed	Discovery	Active (Global)
R7027	Harbour BioMed	Discovery	Active (Global)
ImmCelz™ Platform	Creative Medical Technology Holdings	Preclinical	Research
Gavocabtagene autoleucel	Astellas	Phase 1/2	Active
miR-124 Activator	Formation Bio	Phase 2	Active
Autologous Cell Therapy Collaboration	Lupagen	Preclinical	Active
Autoimmune Diagnostics Leadership Initiative	Vibrant America Clinical Laboratory	Commercial	Active
I&I Portfolio	Third Arc Bio	Pre-clinical	Active
Undisclosed Platform Programs	Zag Bio	Preclinical	Active
E-602	Palleon Pharmaceuticals	IND-Enabling	Active